Elafibranor Granted Priority Review for Primary Biliary Cholangitis

The FDA has accepted for Priority Review the NDA for elafibranor for the second-line treatment of primary biliary cholangitis.

Related Keywords

Christelle Huguet ,Drug Administration ,Head Of Research Development ,Priority Review ,New Drug Application ,Itch Numeric Rating Scale ,